SANGAMO THERAPEUTICS, INC

SGMO

Explore Our Financial Data > Companies > SANGAMO THERAPEUTICS, INC
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
SGMO
CIK0001001233
SIC2836
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupBiological Products, Except Diagnostic Substances

Contact

Address501 CANAL BLVD., RICHMOND, CA, 94084
Website sangamo.com
Phone5109706000
CEOAlexander D. Macrae
Employees480

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$32.88 million
Pre-Tax Income$-109.35 million
Net Income$-108.91 million
Net Income to Common$-107.62 million
EPS$-0.41
View All
Balance Sheet
Cash$29.62 million
Assets$88.64 million
Liabilities$82.40 million
Common Equity$6.24 million
Liabilities & Equity$88.64 million
View All
Cash Flow Statement
Net Income$-108.91 million
Cash From Operating Activities$-76.16 million
Cash From Investing Activities$1.24 million
Cash From Financing Activities$62.94 million
Change in Cash$-10.17 million
View All
Calculations
NOPAT$-76.32 million
EBITDA$-101.17 million
Price to EarningsN/A
Price to Book$24.25
ROE-480.02%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation Signals

Sangamo Therapeutics has seen its price target lowered even as analysts keep their fair value estimate steady at $3.25 per share, which underscores a more measured narrative around risk and reward. Behind this shift, a slightly reduced discount rate of 7.31% alongside stronger long term assumptions for revenue growth reflects a blend of greater regulatory clarity, an extended cash runway, and ongoing concerns over execution and partnering timelines. Stay tuned to see how investors can track...

Article Link

Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight

DelveInsight's Hemophilia A Market Insights report includes a comprehensive understanding of current treatment practices, hemophilia A emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Article Link

BC-Most Active Stocks

HIVE Digital Technologies Ltd. 3,360,326 3.35

Article Link

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. Fast Track Designation aims to facilitate the development and expedite the review of new therapeutics that are inte

Article Link

How Recent Developments Are Rewriting the Story for Sangamo Therapeutics

Following its latest earnings and regulatory guidance, Sangamo Therapeutics has seen its fair value estimate hold steady at $3.25 per share, while its discount rate ticked up marginally from 7.28% to 7.34%. This modest change reflects a careful balance between confidence in the company's regulatory progress and recognition of ongoing risks tied to future partnerships and deal-making. Continue reading to find out how investors can stay informed as the story around Sangamo's future continues to...

Article Link